Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 968 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 968 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $99,994.40. Following the sale, the senior vice president directly owned 4,503 shares in the company, valued at $465,159.90. The trade was a 17.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Jolanda Howe also recently made the following trade(s):

• On Monday, January 26th, Jolanda Howe sold 842 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $96.19, for a total transaction of $80,991.98.
• On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $86,423.58.

Mirum Pharmaceuticals Stock Up 1.6%

MIRM stock traded up $1.65 on Tuesday, reaching $105.45. 670,739 shares of the company traded hands, compared to its average volume of 775,404. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $105.64. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The company has a market cap of $5.42 billion, a P/E ratio of -122.61 and a beta of 0.49. The firm has a fifty day simple moving average of $81.60 and a 200-day simple moving average of $73.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The business had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. During the same period in the previous year, the company posted ($0.30) earnings per share. The company’s revenue for the quarter was up 47.1% compared to the same quarter last year. Research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on MIRM shares. Leerink Partners set a $100.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, December 10th. JMP Securities set a $95.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Finally, TD Cowen reissued a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $107.25.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in MIRM. MCF Advisors LLC raised its stake in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the third quarter worth $33,000. Comerica Bank increased its position in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the last quarter. Quarry LP bought a new position in Mirum Pharmaceuticals in the third quarter valued at about $41,000. Finally, CWM LLC boosted its position in Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after purchasing an additional 161 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.